Establishment of a PDT Patient Registry

Establishment of a Registry for Patients Treated With Photodynamic Therapy (PDT)

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03589456

Enrollment

Registered

2018-07-17

Start date

2019-01-18

Completion date

2020-01-15

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

lung cancer, lung carcinoma, lung metastases, metastases

Brief summary

This is a non-intervention patient registry to gather data on the use of photodynamic therapy under real-life conditions. It will involve up to 20 sites in USA.

Detailed description

The purpose of this patient registry is to collect information about a patient's cancer treatment, photodynamic therapy (PDT), used alone or in combination with surgery, chemotherapy and radiotherapy. Patients will be registered either before or after PDT is performed, regardless of the indication. Analysis of this information may help to refine the treatment care. Data collected in the registry includes patient characteristics/demographics, disease characteristics, treatment details (photodynamic therapy, radiation, chemotherapy, surgery, etc.), side effects, and survival outcomes. By participating in this registry, patients will not be asked to do anything that would not ordinarily be done as a matter of routine care including clinical assessments, laboratory tests, radiology procedures, and treatments. Information on disease, condition, and treatment will be recorded in the registry during routine visits.

Interventions

OTHERNo intervention

There are no interventions associated with this registry as it is purely observational.

Study design

Observational model

CASE_ONLY

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* All adult patients (≥ 18 years of age) treated with PDT. * Women and men and members of all races and ethnic groups. * Subjects may have received prior treatment for their cancer. * Subjects to give a written informed consent for prospectively collected data.

Exclusion criteria

* None.

Design outcomes

Primary

Measure	Time frame	Description
PDT Outcome	Up to 5-year follow-up	Collection of information on patient characteristics, disease sites, and utilization of prior or combined treatments to evaluate the impact of these parameters on the treatment outcome

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026